Open Orphan PLC's (LON:ORPH) Cathal Friel tells Proactive its subsidiary hVIVO has signed a £4mln contract to conduct a human challenge study for an unnamed top-three global pharma company. The trial will take place at hVIVO’s London quarantine unit and is expected to be completed by the end of the first quarter next year.
Open Orphan's Cathal Friel hails £4mln contract with top-three global pharma firm
Quick facts: Open Orphan PLC
Price: 26.5 GBX
Market Cap: £176.46 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Open Orphan PLC named herein, including the promotion by the Company of Open Orphan PLC in any Content on the Site, the Company receives from...FOR OUR FULL DISCLAIMER CLICK HERE